HS3ST5: A Potential Drug Target for Vascular, Wound, Cancer and Inflammatory Diseases

Target Name: HS3ST5

NCBI ID: G222537

HS3ST5

HS3ST5: A Potential Drug Target for Vascular, Wound, Cancer and Inflammatory Diseases

HS3ST5, also known as heparan sulfate 3-O-sulfotransferase 5, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the heparin biosynthesis pathway, which is involved in the production of the extracellular matrix (ECM ) components that contribute to tissue repair and regeneration.

The heparin biosynthesis pathway involves a series of enzymes that convert simple sugars, such as glucose, to heparin. The first step in this pathway is the conversion of glucose 6-phosphate to glucose 1,6-dimer, which is then converted to heparin using the enzyme HS3ST2.

HS3ST5 is a key enzyme in this pathway, as it catalyzes the transfer of the sulfate group from the 3-O-sulfotransferase moiety of HS3ST2 to the 5-O-sulfotransferase moiety. This transfer of the sulfate group is critical for the production of stable and functional heparin.

HS3ST5 is also involved in the production of other ECM components, including chondroitin sulfate and dermatan sulfate. These molecules are important for maintaining tissue structure and integrity, as well as providing extracellular signals that regulate cell-cell and cell-tissue interactions.

The potential drug target for HS3ST5 is related to the regulation of heparin biosynthesis and the production of ECM components. Heparin is a widely used drug for the prevention and treatment of blood clots, and there is growing interest in developing new and more effective heparin drugs.

HS3ST5 may be a promising drug target for the treatment of various conditions that are related to the regulation of heparin biosynthesis and the production of ECM components. These conditions include:

1. Vascular diseases, such as heart failure, hypertension, and deep vein thrombosis.
2. Wound healing and tissue regeneration.
3. Cancer, particularly breast cancer.
4. Inflammatory diseases, such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD).

The ability of HS3ST5 to regulate heparin biosynthesis and the production of ECM components makes it an attractive drug target for the treatment of various conditions. Further research is needed to understand the full potential of HS3ST5 as a drug target and to develop effective treatments.

Protein Name: Heparan Sulfate-glucosamine 3-sulfotransferase 5

Functions: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to position 3 of glucosamine residues in heparan. Catalyzes the rate limiting step in the biosynthesis of heparan sulfate (HSact). This modification is a crucial step in the biosynthesis of anticoagulant heparan sulfate as it completes the structure of the antithrombin pentasaccharide binding site. Also generates GlcUA-GlcNS or IdoUA-GlcNS and IdoUA2S-GlcNH2. The substrate-specific O-sulfation generates an enzyme-modified heparan sulfate which acts as a binding receptor to Herpes simplex virus-1 (HSV-1) and permits its entry

The "HS3ST5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HS3ST5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets